Literature DB >> 6093716

The presence of abnormal lysosomes in lymphocytes and neutrophils during chloroquine therapy: a quantitative ultrastructural study.

C J Jones, R S Salisbury, M I Jayson.   

Abstract

Lysosomal ultrastructure in circulating lymphocytes and neutrophils from the blood of 22 patients with rheumatoid arthritis or systemic lupus erythematosus undergoing chloroquine therapy has been examined and compared with that of rheumatoid cases receiving alternative forms of treatment and non-rheumatoid controls. The lymphocytes of all 22 patients receiving chloroquine showed a highly significant number of lamellar inclusion bodies (mean 9.3%) compared with only occasional inclusions in six of the 14 rheumatoid and four of the 12 non-rheumatoid controls (means 0.86% and 0.83% respectively). Neutrophils from eight chloroquine-treated patients also showed abnormal granules which were absent from both control groups. These findings confirm our earlier in vitro work which indicated that lymphocytes, compared with neutrophils, had a greater susceptibility to chloroquine action with respect to alterations in lysosomal structure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093716      PMCID: PMC1001513          DOI: 10.1136/ard.43.5.710

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  11 in total

1.  Basic cellular lesion in chloroquine toxicity.

Authors:  W K Read; W W Bay
Journal:  Lab Invest       Date:  1971-03       Impact factor: 5.662

2.  Action of chloroquine phosphate in rheumatoid arthritis. 1. Immunosuppressive effect.

Authors:  G S Panayi; W A Neill; J J Duthie; J N McCormick
Journal:  Ann Rheum Dis       Date:  1973-07       Impact factor: 19.103

3.  Formation of myeloid bodies in rat liver lysosomes after chloroquine administration.

Authors:  R Abraham; R Hendy; P Grasso
Journal:  Exp Mol Pathol       Date:  1968-10       Impact factor: 3.362

4.  Effect of chloroquine on morphology of leukocytes and pancreatic exocrine cells from the rat.

Authors:  M E Fedorko
Journal:  Lab Invest       Date:  1968-01       Impact factor: 5.662

5.  Antimalarial treatment of rheumatoid arthritis.

Authors:  N J Zvaifler
Journal:  Med Clin North Am       Date:  1968-05       Impact factor: 5.456

6.  Prednisolone inhibits phagocytosis by polymorphonuclear leucocytes via steroid receptor mediated events.

Authors:  C J Jones; K J Morris; M I Jayson
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

7.  Inhibition of lysosomal phospholipase A and phospholipase C by chloroquine and 4,4'-bis(diethylaminoethoxy) alpha, beta-diethyldiphenylethane.

Authors:  Y Matsuzawa; K Y Hostetler
Journal:  J Biol Chem       Date:  1980-06-10       Impact factor: 5.157

8.  Chloroquine: its effect on leucocyte auto- and heterophagocytosis.

Authors:  C J Jones; M I Jayson
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

9.  Effect of chloroquine on morphology of cytoplasmic granules in maturing human leukocytes--an ultrastructural study.

Authors:  M Fedorko
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

10.  Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1.

Authors:  M Wibo; B Poole
Journal:  J Cell Biol       Date:  1974-11       Impact factor: 10.539

View more
  3 in total

1.  Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro.

Authors:  M T Labro; C Babin-Chevaye
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

2.  Morphological study of peripheral nerve changes induced by chloroquine treatment.

Authors:  R Tegnér; F M Tomé; P Godeau; F Lhermitte; M Fardeau
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

Review 3.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.